Annoni G, Chirillo R, Swannie D
Clin Biochem. 1986 Aug;19(4):235-9. doi: 10.1016/s0009-9120(86)80033-9.
In 112 prospectively selected patients suffering from acute myocardial infarction (AMI), the serum CK, CK-MB, LD, HBD, AST and m-AST were determined from the time of admission to hospital and every 12 hours for three days in succession. Sixteen of the enrolled patients died due to complications which arose within the first four days of hospitalization while the rest had a favourable outcome. All enzyme activities were determined at 37 degrees C using routine methods; m-AST was measured using an immunochemical method. The statistical analysis of the results demonstrated that 12 hours after admission, serum m-AST and m-AST/AST ratio were significantly higher in the group of non-survivors compared with patients with a favourable prognosis. No significant differences in CK-MB were observed between survivors and non-survivors during the entire period. True and false positive rates were calculated for these and the other enzymes. An optimum decision level of 34 IU/L was chosen for m-AST and 10% for the m-AST/AST ratio. This gave a percentage of correctly classified patients, after 12 and 24 hours, of 74.9% and 91.9%, respectively. In conclusion, the immunochemical determination of m-AST in patients with AMI seems to be an early prognostic index which is able to distinguish patients with unfavourable outcome.
在112例经前瞻性选择的急性心肌梗死(AMI)患者中,从入院时起连续三天每12小时测定血清肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LD)、α-羟丁酸脱氢酶(HBD)、天门冬氨酸氨基转移酶(AST)和线粒体天门冬氨酸氨基转移酶(m-AST)。16例入选患者因住院头四天内出现的并发症死亡,其余患者预后良好。所有酶活性均采用常规方法在37℃下测定;m-AST采用免疫化学方法测定。结果的统计分析表明,入院12小时后,非存活组患者的血清m-AST和m-AST/AST比值显著高于预后良好的患者。在整个期间,存活者和非存活者之间的CK-MB未观察到显著差异。计算了这些酶和其他酶的真阳性率和假阳性率。m-AST的最佳决定水平选择为34 IU/L,m-AST/AST比值为10%。这使得在12小时和24小时后正确分类患者的百分比分别为74.9%和91.9%。总之,AMI患者中m-AST的免疫化学测定似乎是一种能够区分预后不良患者的早期预后指标。